Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is gearing up to initiate a phase 3 study using its subcutaneous formulation of its candidate VK2735 for the treatment of patients with obesity. It is ...

Viking Therapeutics saw its stock rise by 11% over ... The company's completion of subject enrollment for the Phase 2 clinical trial of VK2735, targeting weight loss, and promising results from ...

In March, Viking Therapeutics completed subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the GLP-1 and glucose-dependent ...

Viking Therapeutics (NASDAQ ... The biotech is studying injectable and oral formulations of VK2735 in clinical trials, and results so far have been impressive. As for stock performance, Viking ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like ...